New Therapeutic Strategy in ALS Based on Metabolic Status and Associated Metabolic Pathways.

Study Purpose:

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects central and peripheral motor neurons. None of the clinical trials conducted have been clearly successful and the disease remains incurable, putting patients' vital prognosis at risk in the medium term. An alteration of the basal metabolism leading to hypermetabolism has been described in several articles in the literature. The causes of this hypermetabolism and the precise exploration of the metabolic pathways involved are still poorly understood. The fibroblasts of ALS patients may be the site of some metabolic disturbances in this disease with a hypothetical specific basal metabolic profile. These cells are adapted to different metabolic explorations such as omnic approaches. Superficial skin biopsy followed by fibroblast culture can provide a considerable biobank. This cellular richness will allow us, in ALS patients and their controls, to perform metabolomic and lipidomic approaches, as well as the quantification transcriptomic approach."

Study Status:

Recruiting

Disease:

Amyotrophic Lateral Sclerosis

Study Type:

Interventional

Type of Intervention:

N/A

Intervention Name:

Samples, Indirect calorimetry, Electrical bioimpedance

Placebo:

Phase:

N/A

Study Chair(s)/Principal Investigator(s):

Hélène BLASCO, MD-PhD, University Hospital, Tours

Clinicaltrials.gov ID:

NCT03984708

Neals Affiliated?

No

Coordinating Center Contact Information

Study Sponsor:

University Hospital, Tours

Estimated Enrollment:

90

Estimated Study Start Date:

01 / 27 / 2020

Estimated Study Completion Date:

01 / 01 / 2024

Posting Last Modified Date:

09 / 30 / 2021

Date Study Added to neals.org:

06 / 13 / 2019